Physician profile
Michelle Devilbiss
NPI 1558827527
$11,696.61
in general payments reported to CMS, 2019-2025
19 companies · $3,845 in 2025
The $3,845 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $682 · 2022: $1,720 · 2023: $2,153 · 2024: $3,297 · 2025: $3,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,155 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,154.96 |
| Education | $139.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,797.61 | 2021-2025 | |
| Amgen INC. | $1,448.88 | 2021-2025 | Enbrel, Evenity, Otezla |
| Novartis Pharmaceuticals Corporation | $1,358.41 | 2021-2025 | |
| Janssen Biotech, INC. | $1,152.58 | 2023-2025 | Tremfya, Simponi Aria |
| Janssen Scientific Affairs, LLC | $697.56 | 2022-2025 | Tremfya |
| Ucb, INC. | $472.26 | 2022-2025 | Bimzelx |
| Pfizer INC. | $393.65 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $294.26 | 2021-2024 | Saphnelo |
| Glaxosmithkline, LLC. | $258.76 | 2021-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $189.93 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.90 | 2023-2024 | |
| Fresenius Kabi USA, LLC | $111.55 | 2023-2024 | Idacio |
| Horizon Therapeutics Plc | $105.15 | 2021-2023 | Krystexxa |
| Genentech USA, INC. | $91.33 | 2021 | |
| Lilly USA, LLC | $86.61 | 2025 | Taltz, Zepbound |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $16.54 | 2025 | |
| Sobi, INC | $14.86 | 2024 | |
| Sandoz INC. | $14.71 | 2025 | Jubbonti |
| Neurometrix INC | $11.06 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Devilbiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.